PMID- 14531907
OWN - NLM
STAT- MEDLINE
DCOM- 20031107
LR  - 20190705
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 123
IP  - 2
DP  - 2003 Oct
TI  - Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic 
      implications.
PG  - 263-70
AB  - In this study, we examined osteopontin (OPN) production in myeloma cells and 
      plasma OPN levels in multiple myeloma (MM) patients. We assessed OPN production 
      in bone marrow cells (BMCs) by immunocytochemistry and enzyme-linked 
      immunosorbent assay (ELISA). We also assessed OPN production in various B-cell 
      malignant cell lines, including three myeloma cell lines by reverse transcription 
      polymerase chain reaction (RT-PCR) and Western blotting. In addition, we measured 
      plasma OPN concentrations by ELISA in 30 MM patients, 21 monoclonal gammopathy of 
      undetermined significance (MGUS) patients and 30 healthy volunteers. As a result, 
      in an immunocytochemical study, abundant OPN was detected in BMCs from overt MM 
      patients, whereas no OPN was detected in BMCs from patients with other 
      haematological diseases, including MGUS. Cultured BMCs from overt MM patients 
      produced more OPN than those from patients with either smouldering MM or MGUS. 
      Myeloma cell lines spontaneously produced OPN. Plasma OPN levels of MM patients 
      were significantly higher than those of MGUS patients and healthy volunteers (P < 
      0.05). Moreover, they correlated with both progression and bone destruction of 
      the disease (P < 0.05). These suggest that myeloma cells actively produce OPN, 
      which possibly contributes to osteoclastic bone resorption in MM. Plasma OPN 
      levels may be a useful biomarker for assessing bone destruction in MM and 
      distinguishing MM from MGUS or smouldering MM.
FAU - Saeki, Yukihiko
AU  - Saeki Y
AD  - Department of Molecular Medicine, Osaka University Graduate School of Medicine, 
      Osaka, Japan. saekiy@omh.hosp.go.jp
FAU - Mima, Toru
AU  - Mima T
FAU - Ishii, Taeko
AU  - Ishii T
FAU - Ogata, Atsushi
AU  - Ogata A
FAU - Kobayashi, Hideyuki
AU  - Kobayashi H
FAU - Ohshima, Shiro
AU  - Ohshima S
FAU - Ishida, Tetsushi
AU  - Ishida T
FAU - Tabunoki, Yuichiro
AU  - Tabunoki Y
FAU - Kitayama, Hitoshi
AU  - Kitayama H
FAU - Mizuki, Masao
AU  - Mizuki M
FAU - Katada, Yoshinori
AU  - Katada Y
FAU - Asaoku, Hideki
AU  - Asaoku H
FAU - Kitano, Masayasu
AU  - Kitano M
FAU - Nishimoto, Norihiro
AU  - Nishimoto N
FAU - Yoshizaki, Kazuyuki
AU  - Yoshizaki K
FAU - Maeda, Masahiro
AU  - Maeda M
FAU - Kon, Shigeyuki
AU  - Kon S
FAU - Kinoshita, Naokazu
AU  - Kinoshita N
FAU - Uede, Toshimitsu
AU  - Uede T
FAU - Kawase, Ichiro
AU  - Kawase I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (SPP1 protein, human)
RN  - 0 (Sialoglycoproteins)
RN  - 106441-73-0 (Osteopontin)
SB  - IM
MH  - Biomarkers, Tumor/*biosynthesis/blood
MH  - Blotting, Western
MH  - Bone Marrow Cells/metabolism
MH  - Bone Resorption/blood/etiology
MH  - Diagnosis, Differential
MH  - Disease Progression
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Multiple Myeloma/complications/diagnosis/*metabolism
MH  - Neoplasm Proteins/*biosynthesis/blood/physiology
MH  - Neoplasm Staging
MH  - Osteopontin
MH  - Paraproteinemias/blood/diagnosis
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Sialoglycoproteins/*biosynthesis/blood/physiology
MH  - Tumor Cells, Cultured
EDAT- 2003/10/09 05:00
MHDA- 2003/11/08 05:00
CRDT- 2003/10/09 05:00
PHST- 2003/10/09 05:00 [pubmed]
PHST- 2003/11/08 05:00 [medline]
PHST- 2003/10/09 05:00 [entrez]
AID - 4589 [pii]
AID - 10.1046/j.1365-2141.2003.04589.x [doi]
PST - ppublish
SO  - Br J Haematol. 2003 Oct;123(2):263-70. doi: 10.1046/j.1365-2141.2003.04589.x.